News
-
Adapt Pharma has initiated a rolling NDA submission for intranasal naloxone for the treatment of opioid overdose, the company said. Adapt licensed the intranasal naloxone formulation from Lightlake Therapeutics in December 2014 and received Fast… Read more . . .
-
PARI Respiratory Equipment has announced that its Kitabis Pak, tobramycin inhalation solution packaged with a PARI LC Plus nebulizer for the treatment of cystic fibrosis, has won a 2015 American Package Design Award, presented by… Read more . . .
-
Turing Pharmaceuticals, which is developing intranasal oxytocin and ketamine products, has announced that it has hired Eliseo Oreste Salinas as President of Research and Development. Salinas was most recently President and Chief Scientific Officer of… Read more . . .
-
The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a 3-year, $3 million grant to Pulmotect for clinical studies of its PUL-042 inhaled therapy for the treatment of respiratory… Read more . . .
-
Approximately 450 OINDP experts gathered May 5-8 in Antibes, France for the 10th anniversary iteration of RDD Europe, which featured scientific presentations and posters, a series of workshops, a technical exhibition, and numerous networking opportunities.… Read more . . .
-
Generex Biotechnology has announced an agreement with NHTherapeutics to co-develop a formulation of leuprolide for delivery by Generex’s RapidMist buccal aerosol technology. Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which is currently approved at higher… Read more . . .
-
According to Boehringer Ingelheim, the FDA has approved its tiotropium bromide/olodaterol soft mist inhaler for the treatment of COPD. The company filed an NDA for the product, which will be marketed as Stiolto Respimat Inhalation… Read more . . .
-
Novartis has announced positive results from several Phase 3 studies of NVA237 glycopyrronium bromide and QVA149 indacaterol/glycopyrronium bromide, both delivered by the Breezhaler DPI for the treatment of COPD. NVA237 is marketed as Seebri Breezhaler… Read more . . .
-
Sunovion Pharmaceuticals has presented results from three studies of Brovana arformoterol tartrate inhalation solution for the treatment of COPD at ATS 2015. According to Sunovion, the studies show that Brovana produces clinically significant improvement in… Read more . . .
-
Boehringer Ingelheim Pharmaceuticals has presented new data analyses from two Phase 3 studies of its tiotropium/olodaterol Respimat SMI for the treatment of COPD at ATS 2015. The two efficacy and safety studies (NCT01431274 and NCT01431287),… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.